Tag: Shionogi

May 4, 2021 Off

ViiVHC kicked off rolling submission for investigational therapy for HIV prevention

By Dino Mustafić

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for investigational, long-acting, injectable cabotegravir for the prevention of HIV, also called pre-exposure prophylaxis, or PrEP.  

July 5, 2019 Off

ViiV gets EC’s OK for HIV-1 infection drug Dovato

By Dino Mustafić

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, this week said that the European Commission has granted Marketing Authorisation for HIV-1 infection treatment, Dovato.